Table 3. Outcomes of studies only targeting bifurcation lesion at LMCA.
| Author | Follow up | Treatment | LLL | Restenosis | MACE | ||||||
| MB (mm) | SB (mm) | MB (%) | SB (%) | TLR (%) | MI (%) | Death (%) | |||||
| *SD was unavailable. BVS: Bioabsorbale Vessel Scarfolding; CB: conventional balloon; CBL: coronary bifurcation lesion; DCA: directional coronary atherectomy; DCB: drug-coated balloon; DES: drug-eluting balloon; LAD: left anterior descending; LCx: left circumflex; LLL: late lumen loss; LM: left main; LMCA: left main coronary artery; MACE: major adverse cardiac event; MB: main branch; MI: myocardial infarction; pDES: provisional DES; SB: side branch; TLR: target lesion revascularization. | |||||||||||
| Lu, et al.[27] | 6 months | DCB | LM: 0.2 ± 0.2; LAD: -0.0 ± 0.2; LCx: -0.1 ± 0.3 |
NA | NA | 2.9 | 0.0 | 0.0 | |||
| Kobayashi, et al.[32] | 12 months | DCB | 0.1 ± 0.5 | NA | NA | 3.2 | 0.0 | 0.0 | |||
| Lee, et al.[34] | 12 months | DCB | NA | NA | NA | NA | 16.4 | 6.0 | 0.0 (cardiac) 6.8 (all cause) |
||
| DES | NA | NA | NA | NA | 16.7 | 12.5 | 10.7 (cardiac) 21.4 (all cause) |
||||
| Kook, et al.[33] | 12 months | DCB | 1.1 ± 1.1 | 46.2 | 16.7 | 0.0 | 0.00 | ||||
| DES | 0.6 ± 0.9 | 20.0 | 21.6 | 2.0 | 2.0 (cardiac) 3.9 (all cause) |
||||||
| Xiao, et al.[28] | 6M | DES + DCB | LM: 0.3 LAD: 0.1 LCx: 0.3* | NA | NA | NA | NA | NA | |||
| Erdoğan, et al.[44] | 6 months | DCB + pDES/DES | -0.3 ± 0.5 | NA | NA | 0.0 | 0.0 | 0.0 | |||
| Liu, et al.[46] | 12 months | DES + DCB | LM: 0.1 LAD: 0.2 LCx: -0.2* | 15.4 | 7.7 | 6.0 | 0.0 | 0.0 | |||
| 2-DES | LM: 0.2 LAD: 0.2 LCx: 0.4* | 8.6 | 30.4 | 12.0 | 2.0 | 0.0 | |||||
| Ullah, et al.[47] | 36 months | DES + DCB | NA | NA | NA | NA | 0.0 | 5.4 | |||
| 2-DES | NA | NA | NA | NA | 7.7 | 10.3 | |||||
| DES + CB | NA | NA | NA | NA | 10.0 | 5.0 | |||||
| Li, et al.[29] | 12 months | DES + DCB | NA | NA | NA | 12.5 | 4.2 | 0.0 | |||
| 2-DES | NA | NA | NA | 10.3 | 5.2 | 1.7 (cardiac) | |||||
| DES + CB | NA | NA | NA | 7.6 | 3.0 | 1.5 (cardiac) | |||||